Admission
The Call for Admission to the PhD Degree in Pharmaceutical Sciences is issued every year between April and June.
Undergraduates can also apply as long as they achieve the qualification by the date of enrollment in the course.
Possible reference for further information: Dr. Rosa De Vivo tel. 081-678745
Admission procedure
Evaluation of qualifications: admission of candidates is based on the evaluation of their Curriculum studiorum and on the qualifications presented at the time of application. In compiling their CVs, candidates must include the following information:
- date of graduation and grade of the master's degree
- detailed list of exams taken and relative marks
- any scholarships or research grants obtained (and similar qualifications)
- certificates of participation in post-graduate university courses
- certificates of participation in previous research groups
- certificates of participation in internships
- prizes or other qualifications that can be evaluated (eg second degrees, etc.)
The request for admission may possibly be supplemented by a summary of the degree thesis, the list of any scientific publications and a possible reference letter from a university professor.
Linguistic knowledge: Candidates must also demonstrate good knowledge of a foreign language. Knowledge of the foreign language will be assessed by reading and translating a text (identified during the test itself) into the foreign language chosen by the candidate among those determined by the announcement, and a brief conversation on the content of what has been read.
Oral exam: the oral exam is aimed at ensuring a suitable comparative evaluation of the candidates and at ascertaining the preparation and aptitude of the candidate for scientific research. The qualifications and topics covered by the oral exam must be relevant to the relevant scientific-disciplinary sectors of the PhD course; the interview will focus on a specific topic chosen by the candidate from the list that will be available in this page after the opening of the call.
List of selected topics for the 41st cycle of the Doctoral Course in Pharmaceutical Science
Topic |
Title |
Tutor and co-tutor, special fundings (if indicatede) |
Meta-Inflammation as a driver of multiorgan failure: role of persulfidation |
Drs. Bucci Mariarosaria and Cirino Giuseppe |
|
Identification of Novel Ligands for the Cancer-Related Protein CD44 Using NMR and Other
Biophysical Techniques
|
Drs. Carotenuto Alfonso and Marasco Daniela |
|
Bioactive plant extracts traditionally used to reduce menopausal disorders: identification, characterisation of the phytocomplex metabolic profile and functional validation |
Drs. Daglia Maria and Di Minno Alessandro |
|
Targeting KRAS isoforms in cancer |
Drs. De Simone Alfonso and Ruggiero Alessia |
|
Harnessing Artificial Intelligence and Advanced Computational Methods to Develop Next-Generation Immune Checkpoint Modulators for Immuno-Oncology |
Drs. Di Leva Francesco Saverio and Donati Greta |
|
Targeting transient α-synuclein aggregates in Parkinson's disease |
Drs.Fusco Giuliana and De Simone Alfonso |
|
Development of Green Synthetic Methodologies for Stable Isotope-labelled Anticancer Drugs |
Drs. Giustiniano Mariateresa and Irace Carlo |
|
Validation of New Models for Endocrine/Immune Risk Assessment |
Drs. Grumetto Lucia and Santamaria Rita |
|
Exploring the role of N-acyl taurines and its synthetising enzyme Bile Acid-CoA:Amino Acid N-
Acyltransferase in colorectal cancer carcinogenesis
|
Drs. Izzo Angelo Antonio and Borrelli Francesca |
|
Biotechnological development of exosomes for the health and well-being of the skin |
Drs. Laneri Sonia and Greco Giovanni |
|
Development of Nuclear Receptor Modulators for the Treatment of Metabolic Diseases: An
Integrated Approach Based on Artificial Intelligence and Molecular Modeling
|
Drs. Lavecchia Antonio and Greco Giovanni |
|
Exploring the effects of gut microbiota perturbation on DNA methylation program to control intestinal homeostasis and inflammation |
Drs. Lembo Francesca and Buommino Elisabetta |
|
Evaluation of PEA effect in CNS disease: role of the gut microbiota as pharmacological target |
Drs. Mattace Raso Giuseppina and Pirozzi Claudio |
|
Exploration of the antidiabetic and anti-inflammatory chemical space via marine natural products by Diversity Oriented Synthesis (DOS) and/or Fragment-Based Ligand Drug Discovery (FBLDD) approaches |
Drs. Menna Marialuisa and Casertano Marcello |
|
Advanced data-driven models integrating drug utilization to assess and predict the impact of medication adherence on Health Care System |
Drs. Orlando Valentina and Menditto Enrica |
|
Design of Novel Bioactive Molecules Targeting and/or Mimicking Specific Protein Hot-Spots |
Drs. Persico Marco and Fattorusso Caterina |
|
The aryl hydrocarbon receptor as a therapeutic target in asthma: linking environmental exposure to immune dysregulation |
Drs. Roviezzo Fiorentina and Woo Sheridan |
|
Innovative Systems for Localized Delivery of Anticancer Drugs: From Development to Preclinical Validation |
Drs. Sodano Federica and De Stefano Luca |
|
Soil-Water Interactions and Cyanobacterial Metabolites: From Ecosystem Health to Bioactive
Compound Discovery
|
Drs. Tartaglione Luciana and De Marco Anna |
|
Development of supramolecular peptide nanosystems for the delivery of new
bioinorganic drugs
|
Drs. Tesauro Diego and Morelli Giancarlo |
|
|
New Molecules and Modified Aptamers for Targeting Proteins Involved in Pathological Processes |
Drs. Varra Michela and Galeone Aldo |